Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Perindopril protects against dementia

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7204 p895-899
29 June 2002

This article
Reprint
Photocopy


News summary


Perindopril protects against dementia

A Perindopril-based regimen reduces the chance of patients developing dementia and severe cognitive decline following a stroke, even if they suffer recurrent stroke, a new analysis of data from PROGRESS (perindopril protection against recurrent stroke study) shows.

The analysis examined the risk of developing neurological problems following stroke among 6,105 people randomly assigned to receive perindopril (Coversyl) 4mg plus indapamide 2.5 mg where indicated, or to placebo. The primary endpoint of the trial, reported last year, found that the risk of recurrent stroke or heart attack was reduced by one quarter to one third among normotensive and hypertensive patients treated with perindopril plus indapamide compared with placebo (PJ, 23 June 2001, p842).

During a follow-up period of four years, researchers assessed the rate at which dementia and severe cognitive decline developed among study participants. Overall, patients allocated perindopril-based therapy were 34 per cent less likely to develop dementia after recurrent stroke compared with patients allocated placebo. The risk of severe cognitive decline among perindopril-treated patients fell 19 per cent overall compared with the placebo group, and the active treatment cut the risk of severe cognitive decline among those who suffered a recurrent stroke by 45 per cent compared with placebo.

Dr Christophe Tzourio, Salpetriere Hospital, Paris, said the data underlined the recommendation that perindopril-based therapy should be considered routinely for all patients with cerebrovascular disease. Presenting the data at the International Society of Hypertension meeting in Prague earlier this week, he said: "PROGRESS provides the most compelling evidence to date about the positive effects of blood pressure lowering on the risks of dementia and severe cognitive function."

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20007145

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.